NEW YORK, Nov. 12, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of ViroPharma, Inc. ("ViroPharma" or the "Company") (NasdaqGS: VPHM) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Shire PLC ("Shire"). (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) Click here to learn more about the investigation http://zlk.9nl.com/viropharmavphm/, or call: 877-363-5972. There is no cost or obligation to you. ViroPharma and Shire announced on November 11, 2013, that the companies have entered into a definitive merger agreement under which Shire will acquire all the outstanding common stock of ViroPharma for approximately $4.2 billion. ViroPharma shareholders will receive $50 for each share of ViroPharma stock they own. The investigation concerns whether the ViroPharma Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Shire is underpaying for ViroPharma shares. If you own ViroPharma common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/viropharmavphm/. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Stamford, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph Levi, Esq.Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com SOURCE Levi & Korsinsky, LLP
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.